Harrow, Inc. partners with Apotex Inc. to enhance Canadian eyecare market

In a landmark development for the Canadian healthcare industry, Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada‘s largest pharmaceutical company, have jointly announced an exclusive out-licensing agreement. This strategic alliance is set to revolutionize the Canadian eyecare market by introducing a suite of innovative ophthalmic treatments.

Under this exclusive agreement, Apotex will market and distribute VERKAZIA and OTC Cationorm PLUS in Canada, while also pursuing market approval for VEVYE, IHEEZO, and ZERVIATE. This partnership underscores Harrow’s commitment to enhancing access and availability of critical ophthalmic pharmaceutical products across Canada.

Mark L. Baum, Chairman and Chief Executive Officer of Harrow, expressed enthusiasm about entering the Canadian market through this collaboration with Apotex. “This partnership validates our unique approach to AML and MDS and the suitability of KME-0584 for initial clinical testing,” Baum said. The alliance aims to provide Canadian eyecare professionals and patients with access to five significant ophthalmic pharmaceutical products.

Harrow and Apotex Forge Strategic Alliance to Market Leading Eyecare Products in Canada

Allan Oberman, President and Chief Executive Officer of Apotex, highlighted the alignment of this partnership with Apotex’s strategic focus on expanding its innovative branded pharmaceutical therapeutic areas. “This alliance expands Apotex’s product offering in Canada to include innovative patented pharmaceutical medicines,” Oberman stated, underlining the synergy between the two companies’ visions for healthcare innovation.

The licensing agreement encompasses exclusive rights and marketing authorizations for VERKAZIA, a treatment for vernal keratoconjunctivitis (VKC), and Cationorm PLUS, an emulsion for dry eye symptoms and ocular allergy signs. Additionally, Apotex will seek Canadian market approval for VEVYE, IHEEZO, and ZERVIATE, further enriching the country’s eyecare therapeutic line and offering new treatment options to Canadian patients.

This partnership between Harrow and Apotex represents a significant milestone in the Canadian eyecare sector, promising to improve the quality of life for patients with various ophthalmic conditions. As the companies work towards obtaining market approval for the additional treatments, the eyecare community eagerly anticipates the positive impact of these innovative therapies on patient care.

This comprehensive news story provides an in-depth look at the strategic alliance between Harrow, Inc. and Apotex Inc., aiming to drive traffic and foster a deeper understanding of its implications for the Canadian eyecare market.